Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Want to cut your energy bills? Here’s how five experts are doing it 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
 & Lead Plaintiff Deadline: March 28, 2017 - EconoTimes)
NEW YORK, Feb. 20, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ:EGLT) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Egalet securities between December 15, 2015, and January 9, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/eglt.
The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose material adverse information about its lead product, ARYMO ER and the likelihood that it would receive oral abuse-deterrent labeling.
On January 9, 2017, Egalet released a statement announcing the approval of its product Arymo ER. Later that day, the U.S. Federal Drug Administration stated that a competitor product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Following this news, Egalet stock dropped, thus damaging investors.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/eglt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Egalet you have until March 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
